Ad-hoc | 30 November 2005 18:16

4SC AG: Pre-listing capital increase / Application for stock exchange listing

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Pre-listing capital increase and application for stock exchange listing 4SC AG: Pre-listing capital increase successfully completed / Application for stock exchange listing filed Planegg-Martinsried (Germany), 30 November 2005: 4SC AG (ISIN: DE0005753818), a drug discovery and development company specialising in the research and development of therapeutic agents, today successfully completed its pre- listing capital increase amounting to a total of 10.16 million Euro, coordinated by CONRAD HINRICH DONNER BANK AG, Hamburg, Germany. On the occasion of a private placement, institutional investors as well as existing investors subscribed 2,396,438 shares at the price of 4.24 Euro per share. The company’s share capital thus increases by 2,396,438 to 10,530,077 shares. The additional capital is to be used chiefly for clinical studies and for further extension of the product pipeline. On November 25th, 4SC AG has filed for listing under the regulated market at the Frankfurt Stock Exchange together with admission to the part sector of the regulated market subject to further conditions of admission (Prime Standard). The planned stock exchange listing is not linked to a share capital increase. 4SC AG Am Klopferspitz 19a 82152 Martinsried Deutschland ISIN: DE0005753818 WKN: 575381 End of ad hoc announcement (c)DGAP 30.11.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: The proportion of freely tradeable shares of 4SC AG will be in the region of 25 percent following listing. The shareholding of investors of previous financing rounds, as well as of founders of the company and management is subject to lock up periods of up to 24 months. Since starting its operation in 1999 the company has secured capital resources totalling approximately 44 million Euro, and currently employs 55 people. The original shareholders include venture capital firms 3i, DVC, BioM, BdW, Mulligan Biocapital, Bayern Kapital, KfW Mittelstandsbank and tbg. About 4SC: 4SC develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases (“proof of concept”) and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. The pipeline currently has five projects, the first of which, on the treatment of rheumatoid arthritis, has successfully completed clinical phase I. Preparations for the conduct of the IIa clinical phase are well under way. A further one to two other product candidates should go into clinical development in 2006. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues. For further information please refer to http://www.4sc.de or contact us directly: Bettina von Klitzing Manager Investor Relations und Public Relations 4SC AG Tel.: +49 (0) 89 70 07 63 – 0 Bettina.von.klitzing@4sc.com On behalf of 4SC AG: Regine Petzsch komm.passion Schumacher’s AG Tel.: +49 (0) 89 48 92 72 – 40 Regine.Petzsch@komm-passion.de End of message (c)DGAP